Naproxen/pregabalin conjugate - Xgene Pharmaceutical
Alternative Names: XG 005; XG004 03; XG005 01; XG005 02; XG005 03Latest Information Update: 28 Nov 2023
At a glance
- Originator Xgene Pharmaceutical
- Class Aminobutyric acids; Analgesics; Antiepileptic drugs; Antipyretics; Antirheumatics; Anxiolytics; Drug conjugates; Gabapentinoids; Naphthaleneacetic acids; Neuroprotectants; Nonsteroidal anti-inflammatories; Small molecules
- Mechanism of Action CACNA2D1 protein modulators; Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Postoperative pain
- Phase II Acute pain
- Phase I/II Back pain; Neuropathic pain
- Phase I Pain
- No development reported Diabetic neuropathies
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for phase-I development in Diabetic-neuropathies in China (Topical, Gel)
- 28 Nov 2023 No recent reports of development identified for phase-I development in Pain in China (Topical, Gel)
- 10 Nov 2023 Efficacy, adverse event and pharmacokinetics data from a phase I trial in Pain presented at the ACR Convergence 2023 (ACR-2023)